ClinicalTrials.gg
RecruitingNCT06806579ARTEUpdated Feb 4, 2025

Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma

An observational study in Hepatocellular Carcinoma (HCC), sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Recruiting at 24 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational

How we know · 4 judgments

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Carcinoma, Hepatocellular by IRCCS Azienda Ospedaliero-Universitaria di Bologna — 9 open to participants now, 9 under way, none of them phase 3. Carcinoma, Hepatocellular · IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Planned enrollment
3rd of 11
1,000 · median 270
Started
2022
with 3 others
Observational
11 of 13
9 open now
Registered
8th of 13
by date

Among the 13 studies in Carcinoma, Hepatocellular by IRCCS Azienda Ospedaliero-Universitaria di Bologna, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is one of 4 that started in 2022, is one of 11 observational ones, and was the 8th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

9 of the 13 studies in Carcinoma, Hepatocellular by IRCCS Azienda Ospedaliero-Universitaria di Bologna are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Carcinoma, Hepatocellular by IRCCS Azienda Ospedaliero-Universitaria di Bologna, or all of them as a file.
02

Study summary

  • Background Hepatocellular carcinoma (HCC), is the fifth most common cancer worldwide and the third leading cause of cancer-related death. In most cases (about 80%), HCC develops in a cirrhotic liver - a condition where the liver has been damaged over time, leading to scarring. This makes treatment more challenging.

This study will gather and analyze data from patients treated in real-world settings to:

  1. Understand the effectiveness and safety of new treatment combinations (e.g., atezolizumab-bevacizumab and durvalumab-tremelimumab).

    Identify the best treatment sequences for patients with advanced liver cancer.

  2. Discover clinical and laboratory markers that predict treatment responses, helping personalize care and optimize outcomes.

By addressing these questions, this study will provide valuable information to healthcare providers and guide future treatment decisions for patients with liver cancer.

Read the detailed description
  • Background Hepatocellular carcinoma (HCC), is the fifth most common cancer worldwide and the third leading cause of cancer-related death. In most cases (about 80%), HCC develops in a cirrhotic liver - a condition where the liver has been damaged over time, leading to scarring. This makes treatment more challenging.
  • New Advances in Treatment Options

For many years, sorafenib was the only approved drug for advanced liver cancer when local treatments like surgery were not possible. However, significant advancements have changed the treatment landscape:

  1. Atezolizumab and Bevacizumab (Immunotherapy Combination):

    In 2019, a groundbreaking study (ImBRAVE-150, Phase 3) demonstrated that combining atezolizumab (an immunotherapy drug) and bevacizumab (an anti-angiogenic drug) significantly improved disease-free survival (time without cancer worsening) and overall survival compared to sorafenib.

    This combination was approved in 2019 by the European Medicines Agency (EMA) and later by the Italian Medicines Agency (AIFA) in 2022.

  2. Durvalumab and Tremelimumab (Dual Immunotherapy):

In February 2024, another combination-durvalumab and tremelimumab-was introduced following the results of the Phase 3 HIMALAYA trial, which also showed improved outcomes compared to sorafenib.

Several other immunotherapy-based combinations, such as camrelizumab-rivoceranib and nivolumab-ipilimumab, are under evaluation and may become available in the future.

  • Why Is This Study Important?

    1. Real-World Effectiveness of Treatments:

      While clinical trials have shown promising results for atezolizumab-bevacizumab and durvalumab-tremelimumab, real-world data-information gathered from everyday clinical practice-are still limited. In particular, there is a lack of real-world evidence for the new durvalumab-tremelimumab combination. This study aims to fill that gap by collecting and analyzing data from patients treated in daily clinical practice.

    2. Understanding Treatment Sequences:

      After completing atezolizumab-bevacizumab or durvalumab-tremelimumab, what is the best next treatment? Currently, the only approved next-line drug is sorafenib, and for third-line treatment in Italy, cabozantinib is the only option. However, there is no clear scientific data on the effectiveness of these treatment sequences.

      As more therapies become available, it will be critical to identify the best sequence of treatments to extend survival and improve quality of life.

    3. Identifying Predictors of Response:

      Some patients respond better to treatment than others. This study seeks to identify clinical and laboratory markers that predict which patients will benefit most from specific therapies.

      For example, with sorafenib, the development of certain side effects (like skin reactions) was associated with better survival. It remains unclear whether similar markers exist for newer drug combinations.

      Additionally, the study will examine how factors such as treatment intolerance, patterns of disease progression, and second-line therapies influence survival outcomes.

  • What This Study Aims to Achieve

This study will gather and analyze data from patients treated in real-world settings to:

  1. Understand the effectiveness and safety of new treatment combinations (e.g., atezolizumab-bevacizumab and durvalumab-tremelimumab).

    Identify the best treatment sequences for patients with advanced liver cancer.

  2. Discover clinical and laboratory markers that predict treatment responses, helping personalize care and optimize outcomes.

By addressing these questions, this study will provide valuable information to healthcare providers and guide future treatment decisions for patients with liver cancer.

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)

Keywords

  • atezolizumab
  • bevacizumab
  • tremelimumab
  • durvalumab
  • immunotherapy
  • real-life
  • outcome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Data will be collected from patients with hepatocellular carcinoma (HCC) who are candidates for treatment with atezolizumab-bevacizumab or durvalumab-tremelimumab. Patients will be evaluated in outpatient clinics or inpatient departments of the participating centers as part of the standard care pathway for HCC patients. Data will be collected at the patient's first evaluation and during subsequent assessments (approximately every 3-4 weeks), as per the routine care process for HCC patients receiving pharmacological treatments. The follow-up observation for each patient will continue as part of the standard care pathway.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hepatocellular carcinoma not amenable to locoregional procedures
  • Candidate to frontline systemic treatment with atezolizumab-bevacizumab or other immunotherapies

Exclusion criteria

Exclusion Criteria:

  • Concurrent treatment with other antineoplastic agents
  • Other active neoplasia
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

This study also gives DurvalumabStudies of DurvalumabDurvalumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TremelimumabStudies of TremelimumabTremelimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., AtezolizumabStudies of AtezolizumabAtezolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Evaluate toxicity as first-line therapy

    To evaluate toxicity of therapeutic sequences in which atezolizumab-bevacizumab or other immunothrapies were administered as first-line therapy within the standard care pathway for patients with hepatocellular carcinoma. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: from enrollment up to 3 years from the first dose

Secondary outcomes

  1. Progression-free survival

    defined as the time between the first administration of atezolizumab-bevacizumab or durvalumab-tremelimumab and radiological progression

    Time frame: from enrollment up to 3 years from the first dose

  2. Overall survival

    defined as the time between the treatment start and the death of the patient, or to the last follow-up evaluation

    Time frame: from enrollment up to 3 years from the first dose

  3. Objective response rate (ORR)

    defined as the percentage of patients who achieve a partial or complete response to the disease on follow-up imaging, according to RECIST 1.1 criteria, out of the total number of patients who undergo at least one radiological assessment.

    Time frame: from enrollment up to 3 years from the first dose

  4. Rate of Patients Eligible for Second-Line Treatments

    defined as the percentage of patients who, after the definitive discontinuation of atezolizumab-bevacizumab or other immunotherapies, have sufficiently good general conditions and liver function to allow the prescription of an additional line of systemic treatment.

    Time frame: from enrollment up to 3 years from the first dose

  5. Safety monitoring

    Incidence of Adverse Events Related to Atezolizumab-Bevacizumab or other immunotherapies

    Time frame: from enrollment up to 3 years from the first dose

07

Study locations

16 of 24 sites recruiting
  • Ospedali Riuniti Ancona, Via Conca, 71, 60126 Torrette AN
    Torrette, AN 60126, Italy
    Recruiting
  • I.R.C.C.S. "S. De Bellis", Via Turi, 27, 70013 Castellana Grotte BA
    Castellana Grotte, BA 70013, Italy
    Not yet recruiting
  • AUSL Bologna Via Castiglione 15 40136 Bologna BO
    Bologna, BO 40136, Italy
    Recruiting
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna (Oncology Unit), Bologna, BO 40136
    Bologna, BO 40136, Italy
    Recruiting
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna (Semiotics Unit)
    Bologna, BO 40136, Italy
    Recruiting
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna
    Bologna, BO 40136, Italy
    Recruiting
  • Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione "Garibaldi, Piazza Santa Maria di Gesù, 5, 95123 Catania CT
    Catania, CT 95123, Italy
    Not yet recruiting
  • Ospedali Riuniti. Viale Pinto Luigi, 1, 71122 Foggia FG.
    Foggia, FG 71122, Italy
    Recruiting
  • Ospedali Riuniti. Viale Pinto Luigi, 1, 71122 Foggia FG
    Foggia, FG 71122, Italy
    Not yet recruiting
  • AOU Careggi. Largo G. Alessandro Brambilla, 3. 50134 Firenze FI
    Firenze, FI 50134, Italy
    Recruiting
  • Policlinico di Modena Via del Pozzo, 71, 41125 Modena MO
    Modena, Missouri 41125, Italy
    Not yet recruiting
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. via Francesco Sforza, 28 - 20122 Milano.
    Milano, MI 20122, Italy
    Recruiting
  • ASST Grande Ospedale Metropolitano Niguarda, Piazza dell'Ospedale Maggiore, 3, 20162 Milano
    Milano, MI 20162, Italy
    Not yet recruiting
  • Humanitas Research Hospital. Via Alessandro Manzoni, 56, 20089 Rozzano MI
    Rozzano, MI 20089, Italy
    Recruiting
  • Azienda Ospedaliero- Universitaria Paolo Giaccone. Via Liborio Giuffrè, 5, 90127 Palermo
    Palermo, PA 90127, Italy
    Recruiting
  • Istituto Oncologico Veneto. Via Gattamelata, 64, 35128 Padova PD
    Padova, PD 35128, Italy
    Recruiting
  • AOU Pisana. Via Roma 67. 56126 Pisa PI
    Pisa, PI 56126, Italy
    Recruiting
  • Ospedale degli Infermi Viale Stradone, 9 48018 Faenza (RA)
    Faenza, RA 48018, Italy
    Recruiting
  • IRCCS Santa Maria Nuova Viale Risorgimento, 80, 42123 Reggio Emilia
    Reggio Emilia, RE 42123, Italy
    Not yet recruiting
  • Policlinico Gemelli. Largo Agostino Gemelli, 8, 00168 Roma RM
    Roma, RM 00168, Italy
    Recruiting
  • Azienda sanitaria universitaria Friuli Centrale, Piazzale Santa Maria della Misericordia, 15 33100 Udine (UD)
    Udine, UD 33100, Italy
    Not yet recruiting
  • Azienda Ospedaliera Universitaria Integrata di Verona. Piazzale Aristide Stefani, 1, 37126 Verona VR
    Verona, VR 37126, Italy
    Recruiting
  • P.O. Ospedale del Mare. Via Enrico Russo, 11, 80147 Napoli NA
    Napoli, 80147, Italy
    Recruiting
  • Azienda Ospedaliero- Universitaria Maggiore della Carità, Padiglione G, L.go Bellini, 28100 Novara NO
    Novara, 28100, Italy
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Privacy regulations

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Oct 2030, 94 months after the start.

Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's planned 94 months is above that.

Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2025
First posted
Feb 4, 2025
StartActual
Dec 21, 2022
Primary completionEst.
Oct 31, 2030
CompletionEst.
Oct 31, 2031
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06806579
Responsible party
Sponsor
First posted
Feb 4, 2025
Start date
Dec 21, 2022
Primary completion
Oct 31, 2030 (estimated)
Completion
Oct 31, 2031 (estimated)
Last update
Feb 4, 2025

Study contacts

Francesco Tovoli, MD
Contact
francesco.tovoli@unibo.it
+390512142214
Francesco Tovoli, MD
principal investigator · IRCCS Azienda Ospedaliero-Universitaria di Bologna

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion